Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S53–S57 | Cite as

Respiratory infections: clinical experiences with the new quinolones

  • B. I. Davies
  • F. P. V. Maesen


Nearly 300 patients, admitted to hospital with acute purulent exacerbations of chronic respiratory disease, have been treated with various newer quinolones: 26 patients received enoxacin, 50 pefloxacin, 80 ciprofloxacin and 143 ofloxacin. Dosages varied from 400 mg once daily to 1000 mg twice daily, orally for five to 10 days. Patients were evaluated bacteriologically and clinically before, during and after treatment. Nearly all infections associated withHaemophilus influenzae and/orBranhamella catarrhalis were successfully eradicated. SomeStreptococcus pneumoniae infections relapsed, some could not be eradicated, and a number of patients developed new infections with these organisms. Approximately half of thePseudomonas aeruginosa infections were eradicated. Nearly all patients received concomitant theophylline but this only caused serious problems in those given 600 mg doses of enoxacin twice daily. Five patients given ciprofloxacin had to discontinue because of unwanted effects (mostly hallucinations), one patient given pefloxacin had gastric pain and two patients given ofloxacin developed a skin rash. Apart from the theophylline interaction, the unwanted effects did not appear to be dose-related. The best overal clinical results were noted after 800 mg doses of ofloxacin once daily for seven days.

Key words

Branhamella catarrhalis Ciprofloxacin Enoxacin Ofloxacin Pefloxacin Purulent bronchitis Quinolones Streptococcus pneumoniae 


  1. 1.
    Davies BI, Maesen FPV, Teengs JP. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother 1984;14(Suppl C):83–6.PubMedGoogle Scholar
  2. 2.
    Maesen FPV, Davies BI, Teengs JP. Pefloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1985;16:379–88.PubMedGoogle Scholar
  3. 3.
    Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 1986: 5:226–31.PubMedGoogle Scholar
  4. 4.
    Maesen FPV, Davies BI, Baur C, Sumajow CA. Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease. J Antimicrob Chemother 1986: 18:629–34.PubMedGoogle Scholar
  5. 5.
    Mulder J, Goslings WRO, Van der Plas MC, Lopez Cardozo P. Studies on the treatment with antibacterial drugs of acute and chronic bronchitis caused byHaemophilus influenzae. Acta Med Scand 1952;143:32–49.PubMedGoogle Scholar
  6. 6.
    Davies BI, Maesen FPV, Brombacher PJ, Sjövall J. Twice daily dosage of bacampicillin in chronic bronchitis: a double blind study. Scand J Respir Dis 1978;59:249–56.PubMedGoogle Scholar
  7. 7.
    Davies BI, Maesen FPV, Teengs JP, Baur C. The quinolones in chronic bronchitis. Pharm Weekblad [Sci] 1986;8:53–9.Google Scholar
  8. 8.
    Maesen FPV, Teengs JP, Baur C, Davies BI. Quinolones and raised plasma concentrations of theophylline. Lancet 1984;ii:530.Google Scholar
  9. 9.
    Wijnands WJA, Vree TB, Van Herwaarden CCA. The effect of the 4-quinolone enoxacin on plasma theophylline concentrations. Pharm Weekbl [Sci] 1986;8:42–5.Google Scholar
  10. 10.
    Davies BI, Maesen FPV. Quinolones in chest infections. J Antimicrob Chemother 1986;18:296–9.PubMedGoogle Scholar
  11. 11.
    Ellner PD, Neu HC. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. J Amer Med Assoc 1981;246:1575–8.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • B. I. Davies
    • 1
  • F. P. V. Maesen
    • 2
  1. 1.Department of Medical MicrobiologyDe Wever ZiekenhuisCX HeerlenThe Netherlands
  2. 2.Department of Respiratory DiseasesDe Wever ZiekenhuisCX HeerlenThe Netherlands

Personalised recommendations